EX-99.1 2 opkohealthmanagementpres.htm EX-99.1 opkohealthmanagementpres
September 2020 NASDAQ: OPK

Forward Looking Statements This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “potential,” and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, expectations about COVID-19 testing, the demand for testing, our capacity for testing and expected turnaround time, the impact of COVID-19 on all of our businesses, positively and negatively, our ability to expand our capacity should there be additional demand, the availability of resources, including labor, equipment and supplies, to meet demand for testing and the potential impact on us should these resources be constrained, whether our turnaround time will be as expected or our performance quality decline, our product development efforts and the expected benefits of our products, our estimated revenues and financial projections, including expected Rayaldee and BioReference revenues, whether we will maintain profitability or continue growth at BioReference, whether prescriptions for Rayaldee will stabilize or increase, expected milestones and royalties from the outlicense of our products, the outcome of our clinical trials and validation studies and that such outcomes will support marketing approval or commercialization, the expected market penetration and size of the market for our products, our ability to successfully commercialize our product candidates such as hGH-CTP, Factor VII- CTP, and our rare disease product candidates, whether Rayaldee will raise serum total 25-hydroxyvitamin D (25D) more effectively than any over-the-counter (OTC) or prescription (Rx) products currently marketed without the risk of hypercalcemia, our ability to develop Rayaldee for new indications including stage 5 CKD, and the timeline for doing so, whether the clinical data for hGH-CTP will support submission of a Biologics License Application (BLA), the timing of such submission, and approval for hGH-CTP in adults and pediatric patients, whether we will be required to make any changes to our development plans for hGH-CTP and increase our expenditures, expectations regarding patent coverage, the expected timing for commencing, enrolling, completing and announcing results for our clinical trials, the timing for release of trial data and seeking and obtaining FDA and European regulatory approvals as well as reimbursement coverage for our products. These forward-looking statements are only predictions and reflect our views as of the date they were made, and we undertake no obligation to update such statements. Such statements are subject to many risks and uncertainties that could cause our activities or actual results to differ materially from the activities and results anticipated in forward looking statements including the continued prevalence of COVID-19, liquidity issues and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially viable and competitive products and treatments, the success of our collaboration and relationship with Pfizer and our other commercial partners, general market factors, competitive product development, product availability, federal and state regulations and legislation, delays associated with development of novel technologies, unexpected difficulties and delays in validating and testing product candidates, the regulatory process for new products and indications, manufacturing issues that may arise, the need for and availability of additional capital, the possibility of infringing a third party’s patents or other intellectual property rights, the uncertainty of obtaining patents covering our products and processes and in successfully enforcing them against third parties, and the potential for litigation or government investigations, including all of the risks identified under the heading Risk Factors in our Annual Report on Form 10-K and other filings with the Securities and Exchange September 2020 | 2

Diversified Assets Across Business Units Marketed Pharmaceuticals Pipeline Diagnostics • Rayaldee addresses unmet need in CKD market • Somatrogon once weekly (hGH-CTP) partnered with • BioReference Laboratories revenue of • Rayaldee revenue of $8.6 million in 2Q 2020 Pfizer • ~$251 million in 2Q 2020 • Rayaldee partnered with Vifor Fresenius; Up to • Successful pivotal phase 3 pediatric • Significant response to COVID-19 pandemic; ~5.2 $787 million in milestones with tiered double digit somatrogon study completed; positive topline million PCR tests performed as of September 13 royalties data announced October 2019 2020; leader in mobile testing sites and federal, • Rayaldee partnered in Japan with Japan Tobacco; • Successful Japanese phase 3 pediatric state and local partnerships up to $112 million in milestones with tiered double somatrogon study completed; positive top • 300-person sales and marketing team drives digit royalties line data announced in June 2020 industry leading esoteric testing • Initiating multiple drug study trials in various areas of • Recognized leader in genetic testing unmet need September 2020 | 3

Somatrogon© Summary Achieved Primary Endpoint Secondary Endpoints Achieved • Somatrogon© (hGH-CTP), a once weekly growth hormone • Change in height standard deviation scores at six and 12 replacement therapy, was proven non-inferior to daily months were higher with somatrogon© in comparison to Genotropin® (somatropin) with respect to height velocity somatropin after 12 months • At six months, change in height velocity was higher with • Height velocity at 12 months of treatment was higher in the somatrogon© in comparison to somatropin somatrogon© group (10.12 cm/year) than in the somatropin group (9.78 cm/year) • Somatrogon was generally well tolerated in the study and comparable to that of somatropin dosed once-daily with respect to the types, numbers and severity of the adverse events observed between the treatment arms. Global Partnership with Pfizer Successful Japanese Registration Study • Pfizer to commercialize somatrogon© • Height velocity at 12 months of treatment was higher in the • Highly committed to maintaining global hGH franchise somatrogon© group (9.65 cm/year) than in the somatropin group (7.87 cm/year) • Study met all primary and secondary endpoints and together with the global Phase 3 clinical trial a NDA 1 Pfizer 2018 Annual Report submission is anticipated in 1H 2021 September 2020 | 4

Somatrogon© CTP Technology Somatrogon© (hGH-CTP) consists of the natural peptide sequence of native growth hormone and the 28 amino acids of the C-Terminus Peptide of CTP human chorionic gonadotropin hormone. This molecule, compared to current GH replacement therapies, is designed to reduce the injection frequency from daily to once a week in adults and children with GH deficiencies. hGH September 2020 | 5

Somatrogon© Phase 3 Participation 106 CLINICAL SITES ACROSS 22 COUNTRIES Ukraine Belarus Russia Canada Great Britain Poland Spain Bulgaria South Korea USA Georgia Greece Turkey Japan* Israel Taiwan Mexico India Colombia Australia Argentina New Zealand * Additional separate Phase 3 clinical trial conducted in Japan September 2020 | 6

Somatrogon© Phase 3 Study Design Randomized, open-label Long-term open-label extension 1:1 Randomization treatment period (52 weeks) (Until market approval) Screening (8-12 weeks) Somatrogon© 0.66 mg/kg/week Somatrogon© 0.66 mg/kg/week Genotropin® 0.034 mg/kg/day Eligibility • 224 subjects enrolled in the main study evaluation • 212 subjects currently in long-term open-label extension Primary Endpoint • Annual height velocity at month 12 Secondary Efficacy • Height velocity at month 6 Endpoints • Change in height standard deviation score (SDS) at months 6 and 12 September 2020 | 7

Somatrogon Path To Approval • BLA submission in US anticipated 2H 2020 • Completion of analysis of immunogenicity and safety data from pivotal Phase 3 study and open label extension study • Data from two abstracts was presented at the Endo Society’s “ENDO Online 2020” on June 8th, 2020 • “Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Phase 3” • “Interpretation of Insulin-like Growth Factor (IGF-1) Levels Following Administration of somatrogon (a long- acting Growth Hormone-hGH-CTP” • MAA submission in Europe to follow upon completion of open label study demonstrating benefit and compliance with reduced treatment burden • Study completed in September 2020 • NDA submission in Japan anticipated 1H 2021 • Japanese registration study successful completion announced in June 2020 September 2020 | 8

Diversified Assets Nephrology Marketed Pharmaceuticals Pipeline Diagnostics September 2020 | 9

First and only extended-release Chronic Kidney Disease (CKD) prohormone of active form of vitamin D3 The Silent Killer • 9th Leading cause of death, ahead of breast and • Once daily oral formulation of the prohormone 25D3* addresses significant unmet need prostate cancer • Only product approved by FDA to treat secondary hyperparathyroidism • Prevalence expected to increase due to obesity, (SHPT) in patients with stage 3-4 CKD and vitamin D insufficiency diabetes, and hypertension • Reduces plasma iPTH and increases serum 25D, with safety profile similar • Elevated blood levels of intact parathyroid to placebo hormone (iPTH) arise from vitamin D • Minimal adverse effects on serum calcium or phosphorus, key drivers of insufficiency vascular calcification • High PTH levels promote vascular calcification, a • Total prescriptions of Rayaldee increased 54%** in 2Q 2020 compared to 2Q 2019 and was consistent with the first quarter 1Q 2020 despite COVID-19 major cause of CKD morbidity and mortality restrictions • Updated KDIGO practice guidelines recommend against routine use of vitamin D receptor Healthcare providers have no good options activators and highlight unproven effectiveness to treat SHPT in stage 3-4 CKD except for Rayaldee of vitamin D supplementation ** As reported by IQVIA * 25-Hydroxyvitamin D3 or Calcifediol September 2020 | 10

Rayaldee for Patients with Stage 5 CKD and Vitamin D Insuffiency • Phase 2 open label trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of higher strength Rayaldee in subjects with Vitamin D insufficiency and CKD requiring regular hemodialysis • Commenced September 2018 • Approximately 44 patients being treated for 26 weeks • Interim data released in March 2020 • Topline data expected in 2Q 2021 • Costs shared with Vifor Fresenius and Japan Tobacco September 2020 | 11

FDA-Approved Phase 2 Study with Rayaldee in COVID-19 Patients Title: A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue) Screening Randomization Treatment Follow-up Outcome: DayDay --33 Day 1 Days 1-27 Days 28-42 - Prevention of more serious symptoms - Faster recovery ~160 Patients with mild to 1:1 randomization Loading Dose: Observation only for moderate COVID-19 (~80 per treatment 300 mcg/day for 3 days 14 days (many with stage 3 or 4 group) CKD) Maintenance Dose: 60 mcg/day for 24 days Endpoints: Time to resolution of symptoms and attainment/maintenance of serum 25D levels within 50-100 ng/mL. Timeline: Patients screening to commence later in September or in October 2020; completion expected prior to EOY 2020. Sites: Multiple US sites located in southern Florida, the Central Gulf coast, the Midwest and the Southwest. September 2020 | 12

Diversified Assets Broad Development Pipeline Marketed Pharmaceuticals Pipeline Diagnostics September 2020 | 13

Rare Disease Pipeline In Development MARKET INDICATION PRODUCT PRECLINICAL PHASE 1 PHASE 2 PHASE 3 SIZE hGH-CTP (Adults) Once-weekly injection Growth Hormone Deficiency (GHD) hGH-CTP (Children) Once-weekly injection Factor VIIa-CTP (IV) $0.6B Hemophilia Factor VIIa-CTP (SC) Once-/twice-weekly injection IGF-1 Deficiency IGF-1-CTP $0.2B Once-/twice-weekly Bowel Disorders GLP-2 Agonist $2.0B Once-weekly September 2020 | 14

Diversified Assets One of the Nations Largest Reference Laboratories Marketed Pharmaceuticals Pipeline Diagnostics September 2020 | 15

BioReference Laboratories Overview Leading National 80,000 4,000 Employees - Serving 11 Million First Class Logistics Clinical Laboratory Requisitions Daily 300+ Medical Staff Patients Annually • 1.5M+ pick-ups annually • 17M+ miles driven annually • 475+ cars in the fleet • 450+ drivers in logistics September 2020 | 16

Areas of Focus September 2020 | 17

Targeted Areas of Expertise for Physicians September 2020 | 18

Strategic Laboratory Collaboration OPKO Health’s BioReference Laboratories and Westchester Medical Center Health Network Enter Into Strategic Laboratory Collaboration to Deliver Operational and Diagnostic Services, May 13, 2020 • WMCHealth, 10 hospitals through out the Hudson Valley performing over 7 million tests a year • Provide administrative services, laboratory equipment, supplies, reference testing and outreach services September 2020 | 19

Patient Empowerment “BioReference: The Lab Patients Choose” Patient Portal Consumer-initiated Testing Now offering COVID-19 Antibody Testing September 2020 | 20

BioReference’s COVID-19 Response Serving all 50 states with testing locations in: Elmwood Park, NJ; Melbourne, FL; Gaithersburg, MD; Houston, TX; Campbell, CA • Currently, PCR and/or Antibody Testing is being performed out of NJ, FL, MD, TX and CA • PCR & Antibody turnaround time for “Priority” account is 6 hours once in the lab • Performed ~5.3 million COVID-19 PCR tests as of September 13, 2020 • Capacity to run more than 70,000 PCR tests per day • Capacity to run 400,000 antibody tests per day • Partnering with New York, New Jersey and Florida, multiple cities, municipalities and hospital systems and operating more PCR collection sites than any other commercial laboratory • Highly visible back to work solutions including partnering with NFL, NBA and MLS September 2020 | 21

Leverage Strategic Partnerships to Optimize COVID-19 Testing Access Westchester Multiple Large Municipalities Medical Medical and Center Health Groups Government Network September 2020 | 22

Looking Forward • Many factors continue to drive demand for COVID-19 testing at BioReference Laboratories. o Hospitals desire more PCR testing for patients undergoing elective in- patient and outpatient procedures. o Hospitals will continue to test their employees for both PCR and antibody presence. o Physicians will continue to test their patients for COVID-19 disease. o The general public continues to desire to know their antibody status. • The return of the flu season this fall and winter may have an impact on COVID-19 testing and other respiratory infection testing. • Employers are working through their strategies for employees to return to work which includes both PCR and antibody testing programs. September 2020 | 23

Select Financial Information June 30, 2020 • Cash, cash equivalents & marketable securities: $21.6 million Balance Sheet • Un-utilized $100m unsecured credit facility and $15m available under ABL with J.P. Morgan Chase resulting in more than $136m of capital available • Net investments: $26.3 million • Convertible notes, net: $216.5 million • Common shares outstanding: 669.8 million Capital Structure • Consolidated revenues for 2Q 2020 were $301.2 million compared with $226.4 Income Statement million for 2Q 2019 • - Revenue from services were $251.0 million in 2Q 2020 compared with $178.5 million for 2Q 2019 • Net income for 2Q 2020 was $33.7 million ($0.05 per share) compared with net loss of $59.8 million ($(0.10) per share) for 2Q 2019 September 2020 | 24